Table 2.
Outcomes | N eval | N |
---|---|---|
Median days to neutrophil engraftment, (range) | 18 | 16 (7–30) |
Cumulative incidence of Grade II-IV acute GVHD, Prob. (95% C.I.) | 23 | |
@ 100 days | 30 (14–50)% | |
Cumulative incidence of chronic GVHD, Prob. (95% C.I.) | 23 | |
@ 1 year | 28 (12–48)% | |
@ 2 years | 28 (12–48)% | |
Episodes of infection post HCT | ||
≤100 days | ||
Culture positive bacterial | 10 | |
Invasive fungal | 1 | |
PCP | 0 | |
CMV reactivation | 3 | |
Mycobacteria | 0 | |
Hepatitis B or C | 1 | |
Others | 5 | |
>100 days | ||
Culture positive bacterial | 4 | |
Invasive fungal | 1 | |
PCP | 0 | |
CMV reactivation | 0 | |
Mycobacteria | 0 | |
Hepatitis B or C | 1 | |
Others | 2 | |
Median follow-up of survivors, (range), months | 6 | |
Prior to 1996 (n=2) | 75 (59–90) | |
After 1996 (n=4) | 51 (23–74) | |
Overall survival, Prob. (95% C.I.) | 23 | |
@ 1-y ear | 30 (14–50)% | |
@ 2-years | 30 (14–50)% | |
Primary causes of death | 17 | |
Disease relapse | 1 (6%) | |
NRM | ||
Regimen-related toxicities | ||
Pulmonary toxicity | 6 (35%) | |
Other organ toxicities | 3 (19%) | |
Graft failure | 1 (6%) | |
Infections | 4 (24%) | |
GVHD | 1 (6%) | |
Others | 1 (6%) |
GVHD, graft-versus-host disease; PCP, pnemocystis carinii pneumonia; CMV, cytomegalovirus; NRM, non-relapse mortality